Salute e Benessere
Intraoperative Radiation Therapy Market to Double by 2030 Driven by Precision Oncology and Growing Cancer Incidence | DataM Intelligence
The adoption of IORT is accelerating due to its proven ability to deliver concentrated radiation doses directly to the tumor bed during surgery, thereby reducing recurrence and improving survival outcomes.
Hospitals that implement IORT have reported up to and compared to traditional external beam radiotherapy. The technology also cuts hospital stay durations by an average of , resulting in significant cost efficiencies.
DataM Intelligence estimates that over were diagnosed in North America in 2024 alone, accounting for nearly , highlighting the region's early adoption of intraoperative modalities.
The IORT market includes , and such as installation, calibration, and training. The accounts for approximately , with leading at share in 2024. Service-related offerings are expected to grow at , driven by rising system installations and maintenance contracts across hospitals and clinics.
The market is segmented into and . Electron IORT dominates with around , favored for its precision and reduced radiation leakage. Intraoperative brachytherapy, though smaller, is growing at , supported by adoption in specialized oncology centers and low-energy X-ray systems for superficial cancers.
represents the largest application area, accounting for of total IORT procedures in 2024, equating to approximately in revenue. Brain tumor and gastrointestinal cancer applications follow, together comprising of the global market. The breast cancer segment continues to expand at , supported by clinical validation and cost-effectiveness compared to prolonged external radiotherapy.
dominate the market, holding nearly in 2024, as major tertiary centers integrate IORT systems into oncology surgery departments. are the fastest-growing end-user segment with , reflecting the trend toward outpatient cancer treatments and the availability of compact mobile IORT units.
The United States leads the global market with approximately , translating to in revenue. This dominance stems from a dense oncology network, favorable reimbursement structures, and active clinical trials validating IORT's long-term benefits. Over in the U.S. now operate IORT systems, a number expected to exceed .
Recent trends show that in
North America are dedicated to breast and colorectal cancer, reflecting the shift toward targeted intraoperative radiation solutions.
Japan holds a modest but rapidly growing share, estimated at (around ). The Japanese market is expanding at a , fueled by government investments in radiation oncology infrastructure and clinical adoption in university hospitals. Recent government initiatives have allocated to enhance localized cancer care technologies, including IORT.
The IORT market is moderately consolidated, with leading manufacturers and research-driven centers driving innovation through collaborations and product advancements.
Carl Zeiss AG, Ariane Medical Systems Ltd., Eckert & Ziegler, Elekta AB, GMV, iCAD Inc., Moffitt Cancer Center, Xoft, Xinjiang Ke LAN Shuang Yi Medical Technology Stock Co., Ltd, E-Tech Industry Co., Ltd, and Derma Optic and Electronic Technique Co., Ltd.
According to DataM Intelligence, the IORT market will continue its upward trajectory through 2030, propelled by strong adoption in , continuous , and expansion of .
With these developments, the global IORT industry is on course to transition from a specialized niche treatment to a standardized procedure within major oncology care frameworks.
The is emerging as a transformative pillar of precision oncology, combining surgical accuracy with radiation efficacy. With an estimated growth from to , the market reflects a clear shift toward integrated cancer care.
According to , the future of IORT will be shaped by technological miniaturization, service-based business models, and policy support for hospital-based radiotherapy innovation. As more healthcare systems embrace intraoperative radiotherapy, the next decade will see IORT evolve into a mainstream, patient-centric oncology solution worldwide.
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.
Sai Kiran
DataM Intelligence 4market Research LLP
Ground floor, DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad , Telangana 500039
+1 877-441-4866
Sai.k@datamintelligence.com
Logo: https://mma.prnewswire.com/media/1858619/3573087/DataM_Intelligence_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/intraoperative-radiation-therapy-market-to-double-by-2030-driven-by-precision-oncology-and-growing-cancer-incidence--datam-intelligence-302599725.html